- Home
- KYMR vs TVTX Comparison
KYMR vs TVTX Comparison
Compare KYMR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- TVTX
- Stock Information
- Founded
- KYMR 2015
- TVTX 2008
- Country
- KYMR United States
- TVTX United States
- Employees
- KYMR N/A
- TVTX N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- KYMR Health Care
- TVTX Health Care
- Exchange
- KYMR Nasdaq
- TVTX Nasdaq
- Market Cap
- KYMR 2.2B
- TVTX 1.9B
- IPO Year
- KYMR 2020
- TVTX N/A
- Fundamental
- Price
- KYMR $29.62
- TVTX $19.68
- Analyst Decision
- KYMR Buy
- TVTX Strong Buy
- Analyst Count
- KYMR 13
- TVTX 13
- Target Price
- KYMR $56.69
- TVTX $33.17
- AVG Volume (30 Days)
- KYMR 591.0K
- TVTX 1.6M
- Earning Date
- KYMR 05-01-2025
- TVTX 05-05-2025
- Dividend Yield
- KYMR N/A
- TVTX N/A
- EPS Growth
- KYMR N/A
- TVTX N/A
- EPS
- KYMR N/A
- TVTX N/A
- Revenue
- KYMR $47,072,000.00
- TVTX $233,175,000.00
- Revenue This Year
- KYMR $44.93
- TVTX $72.95
- Revenue Next Year
- KYMR N/A
- TVTX $53.84
- P/E Ratio
- KYMR N/A
- TVTX N/A
- Revenue Growth
- KYMR N/A
- TVTX 60.55
- 52 Week Low
- KYMR $29.07
- TVTX $5.12
- 52 Week High
- KYMR $53.27
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- KYMR 33.94
- TVTX 45.64
- Support Level
- KYMR $29.83
- TVTX $20.29
- Resistance Level
- KYMR $35.28
- TVTX $20.98
- Average True Range (ATR)
- KYMR 1.79
- TVTX 0.90
- MACD
- KYMR -0.20
- TVTX 0.07
- Stochastic Oscillator
- KYMR 4.54
- TVTX 54.12
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.